Literature DB >> 1712622

Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferon.

S P Langdon1, G J Rabiasz, L Anderson, A A Ritchie, R J Fergusson, F G Hay, E P Miller, P Mullen, J Plumb, W R Miller.   

Abstract

Controversy exists as to whether interferons usefully influence the growth of epithelial carcinomas. A small cell lung carcinoma (SCLC) cell line, WX322, has been derived which is greater than 1000-fold more sensitive to alpha-interferon (IFN) when grown in agar than other reported SCLC cell lines. The WX322 line has been characterised to prove its epithelial origin and its chemosensitivity compared with that of the NCI-H69 small cell line. The WX322 cell line expresses neuroendocrine and epithelial markers and possesses a morphology consistent with SCLC origin. A concentration of 5 IU ml-1 of IFN produced 50% inhibition of colony formation in agar in the WX322 line, whereas a concentration of greater than 10(5) IU ml-1 was required to produce a comparable effect with the NCI-H69 cell line. In contrast, WX322, possessed similar sensitivity to NCI-H69 cells when exposed to a range of cytotoxic agents. Analysis of the cell cycle indicated that IFN increased the percentage of cells in the G0/G1 phase for the WX322 cell line but increased the percentage in S phase for the NCI-H69 line. Growth of the xenograft, from which the cell line was derived, was also inhibited by IFN at doses greater than 10(5) IU/mouse/day. The WX322 cell line whether grown in agar or as a xenograft shows an unusually high sensitivity to IFN and provides an interesting model for studying mechanisms of IFN cytotoxicity to epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712622      PMCID: PMC1972555          DOI: 10.1038/bjc.1991.200

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Recombinant interferon A (IFL-rA) therapy of small cell and squamous cell carcinoma of the lung. A phase II study.

Authors:  B K Olesen; P Ernst; M H Nissen; H H Hansen
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Effects of mouse interferon on human tumour xenografts in the nude mouse host.

Authors:  F R Balkwill; E Proietti
Journal:  Int J Cancer       Date:  1986-09-15       Impact factor: 7.396

4.  Interferons in oncology: current status and future directions.

Authors:  J F Smyth; F R Balkwill; F Cavalli; A Kimchi; K Mattson; N E Niederle; R J Spiegel
Journal:  Eur J Cancer Clin Oncol       Date:  1987-06

5.  Additive and differential biological activity of alpha-interferon A, difluoromethylornithine, and their combination on established human lung cancer cell lines.

Authors:  G Bepler; D N Carney; M M Nau; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

6.  A rapid assay and partial purification of dopa decarboxylase.

Authors:  P Laduron; F Belpaire
Journal:  Anal Biochem       Date:  1968-11       Impact factor: 3.365

7.  Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines.

Authors:  M Munker; R Munker; R E Saxton; H P Koeffler
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

8.  Establishment and identification of small cell lung cancer cell lines having classic and variant features.

Authors:  D N Carney; A F Gazdar; G Bepler; J G Guccion; P J Marangos; T W Moody; M H Zweig; J D Minna
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

9.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

Authors:  A F Gazdar; D N Carney; M M Nau; J D Minna
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

10.  Monoclonal antibody 123C3 in lung tumour classification. Immunohistology of 358 resected lung tumours.

Authors:  W J Mooi; S S Wagenaar; D Schol; J Hilgers
Journal:  Mol Cell Probes       Date:  1988-03       Impact factor: 2.365

View more
  1 in total

Review 1.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.